In 2017, CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) with axicabtagene ciloleucel (axi-cel) for DLBCL patients who were either refractory to second line chemotherapy or relapsed after autologous stem cell transplant demonstrated an overall response rate (ORR) of 82% and complete response (CR) rate of 58% with a 5 year OS of 42.6%, confirming the curative potential of this cellular therapy in the third line (3L) or later setting [10, 11]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.